米国のバイオ技術及び遺伝学産業年鑑2015:市場統計、動向、主要企業分析

◆英語タイトル: Plunkett's Biotech & Genetics Industry Almanac 2015: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies
◆商品コード:PLUK4120301
◆発行会社(リサーチ会社):Plunkett Research
◆発行日:2014年12月3日
◆ページ数:565
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆販売価格オプション(消費税別)
Single UserUSD350 ⇒換算¥36,400見積依頼/購入/質問フォーム
Corporate License(全社内共有可)USD1,995 ⇒換算¥207,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はPlunkett Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Plunkett Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

PLUNKETT’S BIOTECH & GENETICS INDUSTRY ALMANAC 2015

Key Findings:

-Plunkett Research lists top 400 companies in the Biotech & Genetics and names top trends changing the industry for the mid term.

Key Features:

-Industry trends analysis, market data and competitive intelligence
-Market forecasts and Industry Statistics
-Industry Associations and Professional Societies List
-In-Depth Profiles of hundreds of leading companies
-Industry Glossary
-Buyer may register for free access to search and export data at Plunkett Research Online
-Link to our 5-minute video overview of this industry

Pages: 565
Statistical Tables Provided: 16
Companies Profiled: 396
Geographic Focus: Global

A complete market research report, including forecasts and market estimates, technologies analysis and developments at innovative firms. You will gain vital insights that can help you shape your own strategy for business development, product development and investments.
-How is the industry evolving?
-How is the industry being shaped by new technologies?
-How is demand growing in emerging markets and mature economies?
-What is the size of the market now and in the future?
-What are the financial results of the leading companies?
-What are the names and titles of top executives?
-What are the top companies and what are their revenues?

Contents, Statistics, Forecasts and Analysis Include:
Major Trends Affecting the Biotech & Genetics Industry
1) The State of the Biotechnology Industry Today
2) A Short History of Biotechnology
3) Ethanol Production Soared, But U.S. Federal Subsidy Expires
4) Major Drug Companies Acquire or Partner With Smaller Biotech Firms
5) U.S. Drug Manufacturers Seek Tax Breaks by Acquiring Overseas Firms
6) From Korea to India to Singapore to China, Nations Compete Fiercely in Biotech Development
7) Patients’ Genetic Profiles Plummet in Price as DNA Sequencing Technologies Advance
8) Gene Therapies Target Defective Genes/CRISPR Advances DNA Editing
9) Vaccines and Viruses in Drug Delivery
10) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Growth Continues/Drug Prices Soar
11) Biotech and Orphan Drugs Create New Revenues for Drug Firms
12) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce
13) Drug Delivery Systems Evolve to Meet the Needs of Biotech Drugs
14) Stem Cells—Multiple Sources Stem from New Technologies
15) Government Support for Stem Cell Research Evolves
16) Stem Cells—Therapeutic Cloning Techniques Advance
17) Stem Cells—A New Era of Tissue Replacement Takes Shape
18) Nanotechnology Converges with Biotech
19) Genetically Modified Seeds and Crops (GMOs)
20) Genetically Modified (GM) Foods
21) Molecular Farming of Plant-Based Pharmaceuticals
22) Cloning of Farm Animals/Meat Grown in the Laboratory
23) Selective Breeding, Zinc Fingers and Mutagenesis as Alternatives to GMOs
24) Immunotherapy Promises New Approach to Fighting Cancers
25) Technology Discussion—Genes and DNA
26) Technology Discussion—Proteins and Proteomics
27) Technology Discussion—Microarrays
28) Technology Discussion—DNA Chips
29) Technology Discussion—SNPs (“Snips”)
30) Technology Discussion—Combinatorial Chemistry
31) Technology Discussion—Synthetic Biology
32) Technology Discussion—Recombinant DNA
33) Technology Discussion—Polymerase Chain Reaction (PCR)

Biotech & Genetics Industry Statistics
1) Biotech Industry Overview
2) The U.S. Drug Discovery & Approval Process
3) U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2013
4) U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2013
5) Employment in Life & Physical Science Occupations, U.S.: May 2013
6) Federal R&D & R&D Plant Funding for General Science & Basic Research, U.S.: Fiscal Years 2012-2014
7) U.S. Exports & Imports of Pharmaceutical Products: 2008-1st Quarter 2014
8) U.S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution: 2006-2022
9) U.S. Prescription Drug Expenditures: Selected Years, 1960-2022
10) Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2013
11) Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2013-2015
12) Global Area of Biotech Crops by Country: 2013
13) Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1980-2013
14) Sales by Geographic Area, PhRMA Member Companies: 2012
15) Domestic U.S. Biopharmaceutical R&D & R&D Abroad, PhRMA Member Companies: 1980-2013
16) Domestic U.S. Biopharmaceutical R&D & R&D Abroad Breakdown, PhRMA Member Companies: 2012

【レポートの目次】

Introduction 1
How to Use This Book 3

Chapter 1: Major Trends Affecting the Biotech & Genetics Industry 6
1) The State of the Biotechnology Industry Today 7
2) A Short History of Biotechnology 10
3) Ethanol Production Soared, But U.S. Federal Subsidy Expires 11
4) Major Drug Companies Acquire or Partner With Smaller Biotech Firms 13
5) U.S. Drug Manufacturers Seek Tax Breaks by Acquiring Overseas Firms 13
6) From Korea to India to Singapore to China, Nations Compete Fiercely in Biotech Development 14
7) Patients’ Genetic Profiles Plummet in Price as DNA Sequencing Technologies Advance 16
8) Gene Therapies Target Defective Genes/CRISPR Advances DNA Editing 17
9) Vaccines and Viruses in Drug Delivery 18
10) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Growth Continues/Drug Prices Soar 19
11) Biotech and Orphan Drugs Create New Revenues for Drug Firms 22
12) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce 23
13) Drug Delivery Systems Evolve to Meet the Needs of Biotech Drugs 24
14) Stem Cells—Multiple Sources Stem from New Technologies 25
15) Government Support for Stem Cell Research Evolves 27
16) Stem Cells—Therapeutic Cloning Techniques Advance 28
17) Stem Cells—A New Era of Tissue Replacement Takes Shape 29
18) Nanotechnology Converges with Biotech 30
19) Genetically Modified Seeds and Crops (GMOs) 31
20) Genetically Modified (GM) Foods 32
21) Molecular Farming of Plant-Based Pharmaceuticals 33
22) Cloning of Farm Animals/Meat Grown in the Laboratory 33
23) Selective Breeding, Zinc Fingers and Mutagenesis as Alternatives to GMOs 34
24) Immunotherapy Promises New Approach to Fighting Cancers 34
25) Technology Discussion—Genes and DNA 35
26) Technology Discussion—Proteins and Proteomics 35
27) Technology Discussion—Microarrays 36
28) Technology Discussion—DNA Chips 36
29) Technology Discussion—SNPs (“Snips”) 36
30) Technology Discussion—Combinatorial Chemistry 37
31) Technology Discussion—Synthetic Biology 37
32) Technology Discussion—Recombinant DNA 38
33) Technology Discussion—Polymerase Chain Reaction (PCR) 38

Chapter 2: Biotech & Genetics Industry Statistics 39
Biotech Industry Overview 40
The U.S. Drug Discovery & Approval Process 41
U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2013 42
U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2013 43
Employment in Life & Physical Science Occupations, U.S.: May 2013 44
Federal R&D & R&D Plant Funding for General Science & Basic Research, U.S.: Fiscal Years 2012-2014 45
U.S. Exports & Imports of Pharmaceutical Products: 2008-1st Quarter 2014 46
U.S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution: 2006-2022 47
U.S. Prescription Drug Expenditures: Selected Years, 1960-2022 49
Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2013 50
Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2013-2015 51
Global Area of Biotech Crops by Country: 2013 52
Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1980-2013 53
Sales by Geographic Area, PhRMA Member Companies: 2012 54
Domestic U.S. Biopharmaceutical R&D & R&D Abroad, PhRMA Member Companies: 1980-2013 55
Domestic U.S. Biopharmaceutical R&D & R&D Abroad Breakdown, PhRMA Member Companies: 2012 56

Chapter 3: Important Biotech & Genetics Industry Contacts 57
(Addresses, Phone Numbers and Internet Sites)

Chapter 4: THE BIOTECH 400:
Who They Are and How They Were Chosen 95
Index of Companies Within Industry Groups 96
Alphabetical Index 105
Index of U.S. Headquarters Location by State 108
Index of Non-U.S. Headquarters Location by Country 112
Individual Profiles on Each of THE BIOTECH 400 114
Additional Indexes
Index of Hot Spots for Advancement for Women/Minorities 512
Index by Subsidiaries, Brand Names and Selected Affiliations 514
A Short Biotech & Genetics Industry Glossary 535



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[米国のバイオ技術及び遺伝学産業年鑑2015:市場統計、動向、主要企業分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆